- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.
Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.
Transcript (slightly edited)
What incentives will be necessary for physicians to take on 2-sided risk?
I think there will really have to be some detailed and not as much guarantees, but some really clear metrics, so that they know that they will be achievable in order for the physicians to take 2-sided risk. I think a lot of those are surrounding making sure that we’re all on the same page with accurately measuring quality and what that means to a patient. So some of those could be financial incentives or ensuring that we’re in compliance with certain measure that the physician feels that is really going to drive quality for the oncology patients. You know, making sure that the totality of the patient Is really well defined versus just what’s happening in the clinic at the oncology office.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
